Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

10-04-2019 | Urothelial cancer | Video | Article

Adjuvant chemotherapy for upper tract urothelial cancer

print
PRINT
insite
SEARCH

Speaker: Alison Birtle

Alison Birtle (Rosemere Cancer Centre, Royal Preston Hospital, UK) discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), which led to the POUT trial, and describes the practice-changing implications of the trial for treatment of UTUC (25:06).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Timings:

1:20: What data do we have to guide practice?

2:23: Where does the POUT trial fit into this?

5:20: What did POUT investigate?

8:58: What was the study design?

10:14: What were the results of POUT?

13:08: What are the implications for clinical practice?

16:54: Where does immunotherapy fit in this setting?

20:03: What is the outlook for UTUC?

Speaker disclosures

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits